CSI Market
Sign In | Register

Allarity Therapeutics Inc (ALLR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALLR Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Allarity Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-6.16
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.35
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.79
Operating Lease Right Of Use Asset Amortization Expense-
Lossgain On Investment-
Noncash Leasegain Expense-
Extinguishment Of Debt Gain Loss Income Tax-
Penalty On Series A Preferred Stock Liabilities-
Fair Value Option Changes In Fair Value Gain Loss-
Impairment Of Intangible Assets Excluding Goodwill-
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Operating Lease Liability-
Stock Issued From Conversion Of Warrants-
Conversion Of Stock Amount Issued-
Debt Conversion Converted Instrument Amount-
Dividends Deemed Preferred Stock-
Depreciation Depletion And Amortization Expense Income-0.03
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Gain (Loss) on Sale of Investments0.00
Increase (Decrease) in Income Taxes Receivable0.44
Increase (Decrease) in Accounts Payable-0.17
Increase (Decrease) in Accrued Liabilities-0.70
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense1.27
Other Working Capital-0.20
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.68
Discontinued operations0.00
Net Cash flow from Operating Activities-7.06
Investing Activities
Capital Expenditures-0.06
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Investment Projects0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.06
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments20.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.26
Proceeds from Contributions from Affiliates0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Amount Of Bank Debt-
Penalty On Series A Preferred Stock Liability-
Redemption Of Series B Preferred Stock-
Redemption Of Series A Preferred Stock-
Cash Paid In Connection With Conversion Of Series A Preferred Stock-
Penalty On Series A Preferred Stock Liability-
Payment To Repurchase Of Series B Preferred Stock-
Proceeds From Warrants Exercised In Conjunction With Price Warrant Inducement-
Proceeds From Issuance Of Common Stock And Warrants0.00
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations14.69
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities19.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.12
Total Cash Flow12.29
4 historic quarters locked

Sign in to unlock the full Allarity Therapeutics Inc cash flow history.

Sign In Create Free Account

About Allarity Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-027830

Figures are derived from filed reports and may be restated. Historical data is subject to revision.